Equities Analysts Offer Predictions for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for Unicycive Therapeutics in a report issued on Tuesday, April 1st. Brookline Capital Management analyst K. Raja anticipates that the company will earn ($0.15) per share for the quarter. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at $0.14 EPS.

Separately, HC Wainwright lifted their price objective on shares of Unicycive Therapeutics from $4.00 to $7.50 and gave the company a “buy” rating in a report on Tuesday.

Unicycive Therapeutics Trading Down 12.6 %

Shares of UNCY stock opened at $0.52 on Thursday. The stock has a market cap of $53.55 million, a P/E ratio of -0.53 and a beta of 2.26. The stock has a 50 day moving average of $0.58 and a 200 day moving average of $0.57. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.49.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13).

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Nantahala Capital Management LLC increased its position in shares of Unicycive Therapeutics by 268.5% during the fourth quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company’s stock worth $8,253,000 after purchasing an additional 7,571,636 shares in the last quarter. Vivo Capital LLC raised its holdings in Unicycive Therapeutics by 123.0% in the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company’s stock valued at $7,918,000 after acquiring an additional 5,500,000 shares during the last quarter. Walleye Capital LLC purchased a new position in Unicycive Therapeutics in the 3rd quarter worth approximately $2,040,000. Octagon Capital Advisors LP lifted its stake in Unicycive Therapeutics by 16.8% in the 4th quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company’s stock worth $7,942,000 after purchasing an additional 1,441,000 shares in the last quarter. Finally, Acuta Capital Partners LLC boosted its holdings in shares of Unicycive Therapeutics by 16.4% during the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock worth $1,829,000 after purchasing an additional 323,801 shares during the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.